VPC
CLDX icon

Vestal Point Capital’s Celldex Therapeutics CLDX Stock Holding History

Vestal Point Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,224,165
Closed -$38.8M – 75
2026
Q1 		$38.8M Buy
1,224,165
+59,165
+5% +$1.61M 1.09% 32
2025
Q4 		$31.6M Sell
1,165,000
-40,000
-3% -$1.05M 1.08% 29
2025
Q3 		$31.2M Sell
1,205,000
-545,000
-31% -$12.6M 1.41% 29
2025
Q2 		$35.6M Buy
1,750,000
+1,551,354
+781% +$30.2M 1.88% 18
2025
Q1 		$3.61M Sell
198,646
-106,354
-35% -$2.38M 0.26% 49
2024
Q4 		$7.71M Buy
+305,000
New +$8.29M 0.46% 48

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestal Point Capital's CLDX Position: Q2 2026 in Review

Vestal Point Capital sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 1,224,165 shares — an estimated $38.8M sold.

Vestal Point Capital first reported a position in CLDX in Q4 2024 and held it in 6 quarters. The position peaked at $38.8M in Q1 2026. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Vestal Point Capital reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 1,224,165 Celldex Therapeutics shares in Q2 2026, an estimated $38.8M.
  • Vestal Point Capital first reported a position in Celldex Therapeutics in Q4 2024 and held it in 6 quarters.
  • Vestal Point Capital's Celldex Therapeutics position peaked at $38.8M in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.